 Avrobio Inc NASDAQ: AVRO has reported positive data from the ongoing Phase 2 FAB-GTi Phase 12 trial evaluating AVR-RD-01, an ex vivo lentiviral gene therapy for Fabry disease. 100 reduction, or complete clearance, of the toxic substrate in the kidney biopsy, was observed in the first patient dosed. 